MedTrace Logo

PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease

NCT07146815 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2025-08-28

No results posted yet for this study

Summary

To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)

Conditions

  • NAFLD (Nonalcoholic Fatty Liver Disease)
  • Polycystic Ovarian Syndrome (PCOS)

Interventions

DIAGNOSTIC_TEST

FibroScan

Performance of a FibroScan measurement to determine the prevalence of liver steatosis.

DIAGNOSTIC_TEST

MRI PDFF

Performance of an MRI-PDFF to determine amount of liver steatosis.

Sponsors & Collaborators

  • Ziekenhuis Oost-Limburg

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2025-04-01
Completion
2025-04-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07146815 on ClinicalTrials.gov